Abstract:Conventional genetic approaches and computational strategies have converged on immune-inflammatory pathways as key events in the pathogenesis of late onset sporadic Alzheimer’s disease (LOAD). Mutations and/or differential expression of microglial specific receptors such as TREM2, CD33, and CR3 have been associated with strong increased risk for developing Alzheimer’s disease (AD). DAP12 (DNAX-activating protein 12)/TYROBP, a molecule localized to microglia, is a direct partner/adapter for TREM2, CD33, and CR3. We and others have previously shown that TYROBP expression is increased in AD patients and in mouse models. Moreover, missense mutations in the coding region of TYROBP have recently been identified in some AD patients. These lines of evidence, along with computational analysis of LOAD brain gene expression, point to DAP12/TYROBP as a potential hub or driver protein in the pathogenesis of AD. Using a comprehensive panel of biochemical, physiological, behavioral, and transcriptomic assays, we evaluated in a mouse model the role of TYROBP in early stage AD. We crossed an Alzheimer’s model mutant APP KM670/671NL /PSEN1 Δexon9 (APP/PSEN1) mouse model with Tyrobp −/− mice to generate AD model mice deficient or null for TYROBP (APP/PSEN1; Tyrobp +/− or APP/PSEN1; Tyrobp −/−). While we observed relatively minor effects of TYROBP deficiency on steady-state levels of amyloid-β peptides, there was an effect of Tyrobp deficiency on the morphology of amyloid deposits resembling that reported by others for Trem2 −/− mice. We identified modulatory effects of TYROBP deficiency on the level of phosphorylation of TAU that was accompanied by a reduction in the severity of neuritic dystrophy. TYROBP deficiency also altered the expression of several AD related genes, including Cd33. Electrophysiological abnormalities and learning behavior deficits associated with APP/PSEN1 transgenes were greatly attenuated on a Tyrobp-null background. Some modulatory effects of TYROBP on Alzheimer’s-related genes were only apparent on a background of mice with cerebral amyloidosis due to overexpression of mutant APP/PSEN1. These results suggest that reduction of TYROBP gene expression and/or protein levels could represent an immune-inflammatory therapeutic opportunity for modulating early stage LOAD, potentially leading to slowing or arresting the progression to full-blown clinical and pathological LOAD.

Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Deficiency of TYROBP, an Adapter Protein for TREM2 and CR3 Receptors, is Neuroprotective in a Mouse Model of Early Alzheimer’s Pathology

Deletion of the microglial transmembrane immune signaling adaptor TYROBP ameliorates Huntington’s disease mouse phenotype

Integrated Biology Approach Reveals Molecular and Pathological Interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila Models

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau

Modeling Alzheimer'S Disease In Mouse Without Mutant Protein Overexpression: Cooperative And Independent Effects Of A Beta And Tau

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Inpp5d Deficiency Exacerbates Tau Pathology and Cognitive Deficits in MAPTP301S Mouse

Enhanced Tau Pathology Via RanBP9 and Hsp90/Hsc70 Chaperone Complexes

[O1–14–03]: THE ROLE OF COMPLEMENT C3 AND C3AR RECEPTOR IN TAU PATHOLOGY IN ALZHEIMER's DISEASE

The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease

THE ROLE OF COMPLEMENT C3 AND C3AR RECEPTOR IN TAU PATHOLOGY IN ALZHEIMER’S DISEASE

Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

The Behavioural And Neuropathologic Sexual Dimorphism And Absence Of Mip-3 Alpha In Tau P301s Mouse Model Of Alzheimer'S Disease

Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation

CYP1B1 - RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET